Genomics company Pacific Biosciences of California (NASDAQ: PACB) fell short of the market’s revenue expectations in Q1 CY2026, with sales flat year on year at $37.18 million. Its non-GAAP loss of $0.12 per share was 8.7% above analysts’ consensus estimates.

Is now the time to buy PACB? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

PacBio’s first quarter results were met with a negative market reaction, largely due to revenue coming in below Wall Street expectations as instrument sales remained under pressure. Management highlighted record consumable revenue and over 100% year-over-year growth in shipments to clinically focused accounts as bright spots, but acknowledged that academic funding constraints and lower Vega instrument demand weighed on performance. CEO Christian Henry cited ongoing challenges in the U.S. academic market and shipment disruptions in the Middle East, noting, “Instrument revenue, particularly Vega, was lower than we had expected.”

Looking ahead, PacBio’s outlook is shaped by the anticipated commercial launch of SPRQ-Nx chemistry and increased clinical demand, particularly in Europe and the U.S. Management is optimistic that expanded clinical use cases and the introduction of multi-use SMRT Cells will drive growth in both instrument placements and consumable sales. CFO Jim Gibson cautioned that rising memory component costs will temper gross margin expansion in the near term, while CEO Henry emphasized, “We expect SPRQ-Nx to drive demand for both more Revio systems and more consumables as we expand our clinical opportunity.”

Key Insights from Management’s Remarks

PacBio’s management pointed to robust consumable sales, increased clinical adoption, and a shift in business mix as key drivers of the quarter, while also noting margin pressures from promotional activity and input costs.

• Clinical adoption accelerates: Shipments to clinically focused accounts more than doubled year-over-year, now representing a mid-teens percentage of total consumable shipments. Management sees clinical customers as the primary growth engine, with growing adoption in both the U.S. and Europe.
• Consumables offset weak instruments: Record consumable revenue, up 9% year-on-year, helped mitigate soft instrument sales. Some customers delayed orders in anticipation of the SPRQ-Nx commercial launch, which management expects to further boost consumables in the coming quarters.
• Vega promotion impacts margins: A limited-time promotional program for the Vega instrument drove high placement rates among new customers—over 85% of Vega placements were to new accounts—but compressed average selling prices and contributed to weaker instrument margins. Management ended the promotion after Q1 and expects Vega average prices to normalize.
• EMEA region stands out: Europe, the Middle East, and Africa delivered 17% year-over-year revenue growth, driven by clinical customers moving from pilot to production-scale sequencing. The region is expected to remain the fastest-growing area for PacBio’s business, driven by national health system interest in rare disease testing.
• Cost pressures and strategic refocus: Gross margin was impacted by higher memory component costs and one-time charges. PacBio also completed the sale of its short-read sequencing assets to Illumina, sharpening its focus on long-read sequencing technology and generating $48.1 million in net cash proceeds.

Drivers of Future Performance

Management expects future performance to hinge on clinical market expansion, new chemistry launches, and ongoing cost headwinds, with consumables as the main growth driver.

• SPRQ-Nx launch and adoption: The rollout of SPRQ-Nx chemistry, enabling multi-use SMRT Cells and higher sequencing yield, is anticipated to drive demand for both Revio and Vega systems as well as consumables. Management believes these improvements make long-read sequencing more cost-effective for clinical customers.
• Clinical and commercial growth: PacBio is seeing the transition of clinical customers from validation to full commercialization, particularly in rare disease and newborn screening. Management expects clinical accounts to comprise a growing share of consumable revenue, offsetting ongoing weakness in academic segments.
• Margin headwinds from input costs: Rising memory and computing component prices are expected to limit gross margin improvement in the near term. Management is pursuing R&D solutions for cost reduction but sees continued pressure through 2026, especially as Vega ASPs recover from recent promotional activity.

Catalysts in Upcoming Quarters

In coming quarters, our analysts will closely monitor (1) the commercial adoption and pull-through of SPRQ-Nx chemistry across both Revio and Vega platforms, (2) the pace at which clinical accounts move from pilot to production-scale sequencing, particularly in EMEA and the U.S., and (3) management’s ability to offset gross margin headwinds from rising memory costs. Execution on the Basecamp Research AI project and progress in rare disease and newborn screening studies will also be key indicators.

PacBio currently trades at $1.48, down from $1.65 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.